TB-500 Reconstitution and Dosing: Thymosin Beta-4 in the Literature
Educational map of TB-500 versus thymosin beta-4: how lyophilized vials are discussed, what wound-healing and cardiac papers actually studied, and research-reference ranges versus community loading tables.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Run TB-500 reconstitution math on the web
Use the calculator on this page or peptiq.io, then save the vial in PeptIQ to track doses, supply, reminders, and units-to-draw from your label.
# TB-500 Reconstitution and Dosing: Thymosin Beta-4 in the Literature
> Note: PeptIQ is not a medical provider. This article is educational only. Figures from papers and community logs are not a protocol.
TB-500 is the name most research-vial listings use for a synthetic fragment associated with thymosin beta-4, a 43-amino-acid peptide present in many mammalian cells. Goldstein, Kleinman and colleagues reviewed thymosin beta-4 as a multifunctional regenerative peptide (PubMed 22074294). Cardiac and angiogenesis papers describe a broader biology than the "loading then cruise" tables that dominate forums (PubMed 23045976).
The naming mismatch matters. A vial labeled TB-500 is not automatically the same material, salt, or fill weight used in a thymosin beta-4 clinical or preclinical paper. Reconstitution math assumes the label is true. That assumption is often the weakest part of the story.
Evidence tier
Layer
Strength
Limit
Thymosin beta-4 reviews
Mechanism and wound/angiogenesis framing
Parent peptide, not every TB-500 listing
Cardiac and regeneration papers
Specific models and endpoints
Not a consumer loading calendar
Community logs
What people record as mg and weekly cadence
Observational only
ClinicalTrials.gov indexes thymosin beta-4 studies (search). Registry rows are not a reconstitution recipe.
Lyophilized-vial arithmetic
Educational summaries treat a TB-500 vial the same way they treat other freeze-dried peptides:
A vial labeled 5 mg reconstituted with 2 mL bacteriostatic water is 2.5 mg/mL. A 2.5 mg draw would be 1.0 mL (100 units on a U-100 syringe). A 2.0 mg draw would be 0.80 mL. A 10 mg vial with the same 2 mL of water is 5 mg/mL, so the same milligram target is a smaller volume.
Those conversions explain why two people "on 2.5 mg" can be holding different unit counts. They are not instructions to mix a vial.
Bacteriostatic water is the diluent named most often in community education for multi-draw vials. Product-specific guidance, when it exists, outranks that habit. Storage language is usually lyophilized cold and dark, reconstituted refrigerated, with a conservative beyond-use window measured in weeks rather than months.
What papers report versus what forums schedule
Thymosin beta-4 literature discusses systemic and local exposure in healing and cardiac models. Dose, route, and duration follow the experiment, not a two-week load. Reviews summarize angiogenesis, cell migration, and anti-inflammatory signals. They do not publish a universal milligram-per-week consumer schedule.
Community tables usually split a "loading" block from a lower-frequency "maintenance" block, often in the low-milligram range a few times per week. PeptIQ users who log TB-500 tend to record less-frequent entries than they do for BPC-157, which matches the longer-acting narrative people repeat. That is a logging pattern. It is not a finding that loading works.
Source
Figure people cite
Honest reading
Forum loading tables
Multi-milligram doses, 2x/week for a few weeks
Uncontrolled convention
In-app TB-500 logs
Fewer weekly events than BPC-157
Observational cadence
Thymosin beta-4 papers
Study-specific regimens
Not transferable to an unlabeled vial
Route language in third person
Published work has used several parenteral routes depending on the model. Community education talks about subcutaneous administration because that is how research vials are handled in those discussions. That is route sociology, not an injection tutorial. Needle size, site maps, and sterile technique are outside the scope of this page.
BPC-157 and TB-500 are often logged in the same week. Compatibility claims about drawing two reconstituted solutions into one syringe are chemistry and sterility questions, not a reason to treat either compound as settled. See the mixing and stacking explainers for that context.
Bottom line
TB-500 listings ride on thymosin beta-4 science they may not chemically match. Reconstitution math is generic. Loading calendars are community artifacts. The papers are real. The protocol-shaped tables are not.